From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E] Thu, 23 Apr 2020 11:13:29 +0000 Sent: Fauci, Anthony (NIH/NIAID) [E] To: Subject: FW: seeking your advice on a COVID-19 question Email from Pardis Sabeti. Robert W. Eisinger, Ph.D. Special Assistant for Scientific Projects Immediate Office of the Director National Institute of Allergy and Infectious Diseases National Institutes of Health 31 Center Drive, Room 7A-03 Bethesda MD 20892 Telephone: Email: (b) (6) From: Pardis Sabeti (b) (6) Sent: Wednesday, April 22, 2020 9:47 PM To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) > Cc: Collins, Francis (NIH/OD) [E] Subject: Re: seeking your advice on a COVID-19 question Awe, thank you, here for you two any time, and grateful for the enormous positive impact you have on the world, Pardis On Wed, Apr 22, 2020 at 9:43 PM Fauci, Anthony (NIH/NIAID) [E] < (b) (6) > wrote: Thanks, Pardis. It was great to spend time with you and your colleagues. We learned a lot. Warm regards, Tony From: Collins, Francis (NIH/OD) [E] (b) (6)> Sent: Wednesday, April 22, 2020 8:44 PM (b) (6)> To: Pardis Sabeti < Cc: Fauci, Anthony (NIH/NIAID) [E] Subject: RE: seeking your advice on a COVID-19 question Hey there Pardis, You are much too kind - but we are grateful for YOU and your team! It was fun to talk science for a little while.

-	_	-				
Best,	-	~ 1	20	11		
DEN.	-	<i>r</i> 11	16.			
,		·				

From: Pardis Sabeti Sent: Wednesday, April 22, 2020 8:38 PM To: Collins, Francis (NIH/OD) [E] (6)(6)>Cc: Fauci, Anthony (NIH/NIAID) [E] Subject: Re: seeking your advice on a COVID-19 question Dear Francis and Tony, Thank you for a great conversation. Jacob, Bronwyn, and I stayed on a moment after you left and talked about how inspired we are by each of you and by the camaraderie between you two. Jacob added those two are national treasures, and Bronwyn and I wholeheartedly agreed. Grateful for you both, **Pardis** (6) (6) > wrote: On Wed, Apr 22, 2020 at 8:21 AM Collins, Francis (NIH/OD) [E] Hi Pardis, See attached paper that argues there may be a significant difference in virulence of the COVID-19 clade that predominates on the west coast compared to the east coast. Tony Fauci and I would like to know (b) (5) Also attached is a MedRxiv preprint that describes major differences in pathogenicity of different viral strains. I just got this Can I talk with you later today after you have a chance to review this? Thanks, Francis Pardis Sabeti, MD, DPhil Professor, Harvard University & Harvard T.H. Chan School of Public Health Broad Institute of MIT and Harvard Howard Hughes Medical Institute

Assistant: (b) (6)
Phone: (b) (6)

Website: www.sabetilab.org

**

Pardis Sabeti, MD, DPhil
Professor, Harvard University & Harvard T.H. Chan School of Public Health
Broad Institute of MIT and Harvard
Howard Hughes Medical Institute

Assistant (b) (6) >

Phone: (6) (6)

Website: www.sabetilab.org

From: (b) (6)

 Sent:
 Thu, 23 Apr 2020 07:09:44 -0400

 To:
 Conrad, Patricia (NIH/NIAID) [E]

Subject: Fwd: invitation to New Zealand conversation

Sent from my iPhone

Begin forwarded message:

From: Pat Brittenden <info@blindfish.media> Date: April 23, 2020 at 12:02:13 AM EDT

To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >

Subject: invitation to New Zealand conversation

Good afternoon Dr Fauci,

We are interested in seeing if you would be available for a chat via Zoom to New Zealand about COVID-19

The US is an essential part of the NZ economy contributing between \$1.5 and \$2 billion dollars annually from tourism alone and we would love to have a conversation about where the US is at, how COVID-19 is being dealt with, and the future of things that could lead up to opening our borders again.

We're happy to have you for any length of time, but if you have 10-20 minutes that would be amazing.

Thank you for what you are doing in this global event, I hope we can connect sometime soon

Sincerely,

.

Pat Brittenden www.theDOC.nz www.patbrittenden.com/about From:

(b) (6)

Sent:


Thu, 23 Apr 2020 07:08:26 -0400 Barasch, Kimberly (NIH/NIAID) [C]


To: Subject:

Fwd: Global Health Leaders Call, Thursday, 23 April, 14:30 CET

Sent from my iPhone

Begin forwarded message:






Dear colleagues,

Apologies for the mistake in the below subject line.

The meeting starts at 14.30 CET, as mentioned in the email.

Kind regards,

Sophia



(6) (6) SMITH, Ian Michael		
AYLWARD, Raymond Bruce J.	(b) (6)	
Cc: SHOC <shoc@who.int>; Office of the Director-</shoc@who.int>	-General <dgoffice@who.int>;</dgoffice@who.int>	
SCHWARTLANDER, Bernhard F.	(b) (6); MAHJOUR, Jaouad	
(b) (6):>; FALL, Ibrahima Soce	(b) (6); GREIN, Thomas	
(b) (6):>; MINHAS, Raman	(b) (6); COX, Paul Michael	
(b) (6); AL-SHORBAJI, Farah	(b) (6); POOLE, Marcia	
(b) (6)>; DRURY, Patrick Anthony	(b) (6):>; GRAAFF, Peter Jan	
(b) (6); Dr VAN KERKHOVE, Maria <	6) (6)>; FARES,	
Christine Youssef (b) (6)		
Subject: Global Health Leaders Call, Thursday, 23	April. 14:00 CFT	

Dear colleagues,

Ahead of the Global Health Leaders Call at 14.30 CET today, please find an epidemiological update and analysis attached, in addition to the "Considerations in adjusting public health and social measures in the context of COVID-19" interim guidance document, which was published on the WHO website on 16 April.

Please find below, the key questions for your consideration and input.

- 1. What is your view on the latest epidemiology, virus transmission and severity in affected countries?
- 2. What are the emerging issues/challenges that you see as important?
- 3. What should be the priorities for the 1-2 weeks?
- 4. Any other issues you see as important?

You will be able to connect via the Webex connection below. If you experience any technical difficulties, please contact the WHO HQ EOC operator at: +41 22 79 15 533 or via email: shoc@who.int.

Best,

Sophia

Meeting number (access code): (b) (6), (b) (4)

Meeting password (b) (6), (b) (4)

Thursday, April 23, 2020 2:00 pm | (UTC+02:00) Brussels, Copenhagen, Madrid, Paris |

Join meeting

Join by phone

Tap to call in from a mobile device (attendees only)

(b) (6) TZERLAND Toll

JS Toll

Global call-in numbers

 From:
 Fauci, Anthony (NIH/NIAID) [E]

 Sent:
 Thu, 23 Apr 2020 02:16:12 +0000

To: Alice Park

Subject: FW: Time follow up

Attachments: MedRxiv_Mutations impact pathogenicity SARS-CoV-2_ Lanjuan Li et al.

2020.04.14..pdf

Alice:

Here is another manuscript.

Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 02:11:27 +0000

To: Lou Ignarro

Subject: RE: Greetings- NOT urgent

Lou:

Thank you for your kind note. It is much appreciated. I hope that you are well. Best regards,
Tony

From: Lou Ignarro (b) (6) Sent: Tuesday, April 21, 2020 5:38 PM

To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)

Subject: Greetings- NOT urgent

Hi Tony,

This is Lou Ignarro from UCLA. You and I shared the stage in the "Shoe" at the Ohio State University a few years ago, where you gave the Graduation Address to the undergraduate seniors. I was on stage with you, to receive an award for my basic biomedical research which resulted in my being awarded the Nobel Prize in Medicine in 1998. I recall the nice conversations we were enjoying with Sanjay Gupta while robing for the event.

Thanks for the truly spectacular job you are doing, regarding the coronavirus pandemic. We Nobel Laureates especially regard your work as the most important during our lifetime. Thank you and God bless.

My best wishes,

Lou Ignarro

From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Thu, 23 Apr 2020 01:50:03 +0000

To: Conrad, Patricia (NIH/NIAID) [E]

Cc: Barasch, Kimberly (NIH/NIAID) [C]

Subject: FW: letter from the Governor of Puerto Rico

Attachments: Dr. Anthony S. Fauci, MD[2].pdf

Heads up for a call from the Puerto Rican Health Minister.

From: Pablo L. Peña Antonmarchi <ppena@fortaleza.pr.gov>

Sent: Wednesday, April 22, 2020 5:24 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C]

(b) (6) >; Jennifer M. Storipan <jstoripan@prfaa.pr.gov>; Juan L. Negrón <jnegron@prfaa.pr.gov>; Maria del C Reyes Crespo <mreyes@fortaleza.pr.gov>; Antonio L. Pabon

Batlle <apabon@fortaleza.pr.gov>

Subject: letter from the Governor of Puerto Rico

Importance: High

Dear Dr. Anthony Fauci:

I am sending you for your attention a letter from the Governor of Puerto Rico Hon. Wanda Vázquez Garced.

Cordially,

Pablo L. Peña Antonmarchi

Executive Assistant Lcdo. Antonio Pabón Batlle Chief of Staff Office La Fortaleza San Juan, Puerto Rico



NOTA DE CONFIDENCIALIDAD: Esta transmisión electrónica contiene información perteneciente a la Oficina del Gobernador, que es confidencial, privilegiada y/o privada bajo las leyes aplicables. Solamente podrá ser utilizada por la persona o entidad a la cual se dirige. Si usted no es el destinatario intencional, se le notifica que se prohíbe cualquier uso, diseminación o copia de esta comunicación. Si usted recibe esta comunicación por error, favor de notificar al remitente y eliminar este correo electrónico de su sistema.

CONFIDENTIALITY NOTE: This electronic transmission contains information belonging to the Governor's Office, which is confidential, privileged and exempt from disclosure under the applicable law. It is intended solely for the use of the individual or entity to which it is addressed. If you are not the intended recipient, you are hereby notified that any use, dissemination, or copying of the communication is strictly prohibited. If you have received this communication by error, please notify the sender and delete this e-mail from your system.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 01:40:52 +0000

To: Alice Park; Conrad, Patricia (NIH/NIAID) [E]

Subject: RE: Time follow up

Attachments: Viral Clades Brufsky 42020 Accepted Final.pdf

Alice:

It was great working with you today. Here is the reference. I believe that it will be in the Journal of Medical Virology. It has been accepted, but is no yet in print. Best regards,

Tony

From: Alice Park <alice.park@time.com>
Sent: Wednesday, April 22, 2020 6:30 PM

To: Fauci, Anthony (NIH/NIAID) [E] <AFAUCI@niaid.nih.gov>; Conrad, Patricia (NIH/NIAID) [E]

<conradpa@niaid.nih.gov>
Subject: Time follow up

Dear Dr. Fauci -- many thanks for your time today; we are thrilled to have you as part of the TIME 100 Talks, which will go live tomorrow.

In the meantime, I wanted to double check the reference to the study you mentioned about the east and west coast strains and their potential difference in virulence. Realize it's preliminary, so just wanted to confirm any references we make to it. I checked the biorxiv and medrxiv but didn't find the citation. Would appreciate the journal if it was published. Many thanks! Alice

PLEASE NOTE NEW PHONE NUMBER

Alice Park TIME

(b) (6)

alice.park@time.com @aliceparkny From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 16:29:19 +0000

To: Collins, Francis (NIH/OD) [E] (b) (6)

Cc: Corey MD, Larry (b) (6); Mascola, John (NIH/VRC) [E]

Subject: FW: "final draft"

Attachments: COVID vaccine editorial_prefinal April21_7pm.docx

Francis:

Here is the paper that I mentioned to you and that we are planning to submit to the *NEJM*. I have put your name on it as the senior author. If you are comfortable with that, we will go with it. Please take a look at the manuscript and make any comments or edits that you see fit.

Thanks,

Tony

Fauci, Anthony (NIH/NIAID) [E] From: Sent: Wed, 22 Apr 2020 14:41:09 +0000 To: Billet, Courtney (NIH/NIAID) [E]

Cc: Greg Folkers (b) (6); Conrad, Patricia (NIH/NIAID) [E]

Subject: RE: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief

Fund

I was thinking the very same thing.

Anthony S. Fauci, MD Director National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 Phone: (b) (6) FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6) >

Sent: Tuesday, April 21, 2020 8:43 PM

(b) (6) > To: Fauci, Anthony (NIH/NIAID) [E]

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E]

(b) (6)

Subject: RE: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Ps - what do you want to bet you get invited to throw a first pitch next year?

From: Billet, Courtney (NIH/NIAID) [E] Sent: Tuesday, April 21, 2020 8:38 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E]

(b) (6) >

Subject: FW: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

We're a "go" on this. I'll circle back with his rep tomorrow.

(b)(5) - PC

On Apr 21, 2020, at 6:50 PM, Billet, Courtney (NIH/NIAID) [E] (b) (6) wrote:

Hi guys — as a huge Nats fan, Dr. Fauci very much wants to do this chat with Ryan Zimmerman. Can I get a green light to work on this with them? I'll get the q's but it will be the same general theme as with Steph Curry, YES Network, etc.

From: Judee Ann Williams < judeeann.williams@caa.com>

Sent: Tuesday, April 21, 2020 5:54 PM

To: Billet, Courtney (NIH/NIAID) [E] (b) (6)

Cc: Christine Lancman < christine.lancman@caa.com >; Routh, Jennifer (NIH/NIAID) [E]

Subject: Re: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Absolutely! We would 100% be able to work around that and avoid any association of fundraising.

We would set this up however he will be most comfortable, seed questions in advance, etc. and shed a light on what is most helpful.

Will wait to hear and if you need anything else just let us know. Thank you so much!

From: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)

Date: Tuesday, April 21, 2020 at 4:41 PM

To: Judee Williams < judeeann.williams@caa.com>

Cc: Christine Lancman < christine.lancman@caa.com>, "Routh, Jennifer (NIH/NIAID)

[E]" (b) (6)

Subject: RE: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19

Relief Fund

External Sender

Hi – thanks for your message – we will check and someone will get back to you in the next few days. One caveat is that as a Federal official, Dr. Fauci cannot be associated with fundraising in any way. Please confirm that is something you would be able to work around?

From: Judee Ann Williams < judeeann.williams@caa.com>

Sent: Monday, April 20, 2020 5:21 PM

To: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >; Billet, Courtney (NIH/NIAID)

[E] (b) (6) >

Cc: Christine Lancman < christine.lancman@caa.com>

Subject: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Jennifer & Courtney-

Hello! Our friends from Steph Curry's team passed along your contact information to us and we work at CAA where we represent World Series Champion, Ryan Zimmerman.

Ryan wanted to express his gratitude first & foremost to Dr. Fauci, the entire team and all those behind the scenes working around the clock.

Ryan recently launched the Pros for Heroes Covid-19 Fund last week, with more than 30 professional athletes supporting and over \$300,000 raised across 1,400 separate donations. (<a href="www.prosforheroes.org<">www.prosforheroes.org<). Since its launch last Tuesday, contributions from the Pros For Heroes Fund have gone directly towards PPE needs throughout the Inova hospital network throughout the mid-Atlantic and have helped provide meals to those critical care front-line workers - keeping these front-line heroes covered at work and comfortable at home.

If Dr. Fauci was up to it, Ryan would love to host either a short 15 minute Q&A on his Facebook to continue raising awareness for how we need to be responding to the ongoing crisis. Or even simply thank Dr. Fauci for the tireless work he is doing and shine a light on how folks can support these critical frontline workers.

We are also open to what you think would work best! Would there any openings that would work best?

We know Dr. Fauci is big baseball fan, and of course we are all huge fans of his! If we can ever be supportive or help navigate anything in the world of pop culture, please do not hesitate to ask.

Warmest wishes,

Judee Ann

Judee Ann Williams | Co-Head, CAA Social Impact T: 212-277-5294 | M: (b) (6) | Washington, DC

Pros For Heroes

"Teamwork is the ability to come together towards a common goal. We are looking forward to attracting as many supporters to help join this cause and give back as much as we can to those who have given us so much," said Washington National All-Star, Ryan Zimmerman, the fund's founder.

Social Links:

>https://www.instagram.com/prosforheroes/
>https://twitter.com/prosforheroes

Today Show:

>https://www.today.com/video/ryan-zimmerman-talks-pros-for-heroes-fund-for-feeding-health-care-workers-82202693577<

Washington Post Launch Article:

>https://www.washingtonpost.com/sports/2020/04/14/nationals-ryan-zimmerman-starts-fund-health-care-workers-with-100k-gift/<

This e-mail and any files transmitted with it are intended solely for the use of the individual or entity to whom they are addressed. If the reader of this e-mail is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any use dissemination, forwarding, printing or copying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients are free to do their best work without experiencing harassment and want to ensure they have the relevant resources they need. Clients can go to https://www.caa.com/legal/sexual-harassment-guidelines-caa-clients to learn more about their rights, and how to report violations.

This e-mail and any files transmitted with it are intended solely for the use of the individual or entity to whom they are addressed. If the reader of this e-mail is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any use dissemination, forwarding, printing or copying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients are free to do their best work without experiencing harassment and want to ensure they have the relevant resources they need. Clients can go to https://www.caa.com/legal/sexual-harassment-guidelines-caa-clients to learn more about their rights, and how to report violations.

From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Wed, 22 Apr 2020 00:29:33 +0000

To: Collins, Francis (NIH/OD) [E] (b) (6)

Subject: FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and

mutations affect deadliness of strains, Chinese study finds

More on mutations

From: Fauci, Anthony (NIH/NIAID) [E] Sent: Tuesday, April 21, 2020 1:58 PM

To: Graham, Barney (NIH/VRC) [E] (b) (6)

Subject: FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations

affect deadliness of strains, Chinese study finds

Not peer reviewed, but what do you think?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] < (b) (6)>

Sent: Monday, April 20, 2020 1:53 PM

Subject: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect

deadliness of strains, Chinese study finds

China / Science

Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

- The most aggressive strains of Sars-CoV-2 could generate 270 times as much viral load as the least potent type
- New York may have a deadlier strain imported from Europe, compared to less deadly viruses elsewhere in the United States



Stephen Chen in Beijing

Published: 10:41pm, 20 Apr, 2020 Updated: 1:33am, 21 Apr, 2020



A team led by Professor Li Lanjuan has studied how the novel coronavirus mutates and possible implications for the pandemic. Photo: EPA-EFE

A new study by one of China's top scientists has found the ability of the new coronavirus to mutate has been vastly underestimated and different strains may account for different impacts of the disease in various parts of the world.

Professor Li Lanjuan and her colleagues from Zhejiang University found within a small pool of patients many mutations not previously reported. These mutations included changes so rare that scientists had never considered they might occur.

They also confirmed for the first time with laboratory evidence that <u>certain mutations could create</u> <u>strains deadlier</u> than others.

"Sars-CoV-2 has acquired mutations capable of substantially changing its pathogenicity," Li and her collaborators wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday. Li's study provided the first hard evidence that mutation could affect how severely the virus caused disease or damage in its host.

Li took an unusual approach to investigate the virus mutation. She analysed the viral strains isolated from 11 randomly chosen Covid-19 patients from Hangzhou in the eastern province of Zhejiang, and then tested how efficiently they could infect and kill cells.

The deadliest mutations in the Zhejiang patients had also been found in most patients across Europe, while the milder strains were the predominant varieties found in parts of the United States, such as Washington state, according to their paper.

A separate study had found that New York strains had been imported from Europe. The death rate in New York was similar to that in many European countries, if not worse.

But the weaker mutation did not mean a lower risk for everybody, according to Li's study. In Zhejiang, two patients in their 30s and 50s who contracted the weaker strain became severely ill. Although both survived in the end, the elder patient needed treatment in an intensive care unit.

This finding could shed light on differences in regional mortality. The pandemic's infection and death rates vary from one country to another, and many explanations have been proposed.

Genetic scientists had noticed that the dominant strains in different geographic regions were inherently different. Some researchers suspected the varying mortality rates could, in part, be caused by mutations but they had no direct proof.

The issue was further complicated because survival rates depended on many factors, such as age, underlying health conditions or even blood type.

In hospitals, Covid-19 has been treated as one disease and patients have received the same treatment regardless of the strain they have. Li and her colleagues suggested that defining mutations in a region might determine actions to fight the virus.

"Drug and vaccine development, while urgent, need to take the impact of these accumulating mutations ... into account to avoid potential pitfalls," they said.

Li was the <u>first scientist to propose the Wuhan lockdown</u>, according to state media reports. The government followed her advice and in late January, the city of more than 11 million residents was shut down overnight.

The sample size in this most recent study was remarkably small. Other studies tracking the virus mutation usually involved hundreds, or even thousands, of strains.

Li's team detected more than 30 mutations. Among them 19 mutations – or about 60 per cent – were

They found some of these mutations could lead to functional changes in the virus' spike protein, a unique structure over the viral envelope enabling the coronavirus to bind with human cells. Computer simulation predicted that these mutations would increase its infectivity.

To verify the theory, Li and colleagues infected cells with strains carrying different mutations. The most aggressive strains could generate 270 times as much viral load as the weakest type. These strains also killed the cells the fastest.

It was an unexpected result from fewer than a dozen patients, "indicating that the true diversity of the viral strains is still largely underappreciated," Li wrote in the paper.



Professor Li Lanjuan is a leading Chinese epidemiologist. Photo: Xinhua

The mutations were genes different from the earliest strain isolated in Wuhan, where the virus was first detected in late December last year.

The coronavirus changes at an average speed of about one mutation per month. By Monday, more than 10,000 strains had been sequenced by scientists around the globe, containing more than 4,300 mutations, according to the China National Centre for Bioinformation.

Most of these samples, though, were sequenced by a standard approach that could generate a result quickly. The genes were read just once, for instance, and there was room for mistakes.

Li's team used a more sophisticated method known as ultra-deep sequencing. Each building block of the virus genome was read more than 100 times, allowing the researchers to see changes that could have been overlooked by the conventional approach.

The researchers also found three consecutive changes – known as tri-nucleotide mutations – in a 60-year-old patient, which was a rare event. Usually the genes mutated at one site at a time. This patient spent more than 50 days in hospital, much longer than other Covid-19 patients, and even his faeces were infectious with living viral strains.

"Investigating the functional impact of this tri-nucleotide mutation would be highly interesting," Li and colleagues said in the paper.

Professor Zhang Xuegong, head of the bioinformatics division at the National Laboratory for Information Science and Technology at Tsinghua University, said ultra-deep sequencing could be an effective strategy to track the virus' mutation.

"It can produce some useful information," he said.

But this approach could be much more time consuming and costly. It was unlikely to be applied to all samples.

"Our understanding of the virus remains quite shallow," Zhang said. Questions such as where the virus came from, why it could kill some healthy young people while generating no detectable symptoms in many others still left scientists scratching their heads.

"If there is a discovery that overturns the prevailing perception, don't be surprised."

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E] Sent: Wed, 22 Apr 2020 00:16:44 +0000

To: Collins, Francis (NIH/OD) [E]

Subject: FW: For your attention

Attachments: COVAX2020 - A GLOBAL EFFORT for the ACCELERATED DEVELOPMENT,

PRODUCTION and EQUITABLE ACCESS to COVID-19 VACCINES_16Apr2020_DRAFT.docx

(b) (5) See attachment that Hilary sent me. From: Marston, Hilary (NIH/NIAID) [E] (b) (6) Sent: Tuesday, April 21, 2020 7:44 PM To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6) Subject: Re: For your attention (b) (5) From: Anthony Fauci (b) (6)> Date: Tuesday, April 21, 2020 at 7:30 PM (b) (6) V> To: Hilary Marston < Subject: FW: For your attention Have you heard of this on any of the calls where you represent me?? From: Collins, Francis (NIH/OD) [E] (b) (6) Sent: Tuesday, April 21, 2020 7:28 PM (b) (6); Lane, Cliff (NIH/NIAID) [E] To: Fauci, Anthony (NIH/NIAID) [E]

(b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Freire, Maria (FNIH)

[T] <mfreire@fnih.org>; Wholley, David (FNIH) [T] <dwholley@fnih.org>

Subject: FW: For your attention

Hi all,

See note below from Victor Dzau about a global effort on COVID-19. I can't tell if this is more than a fund-raising effort. I know we have Gates reps on our ACTIV working groups - has any of this plan come up, David?

Francis

From: Dzau, Victor J. <VDzau@nas.edu> Sent: Tuesday, April 21, 2020 4:10 PM

To: Collins, Francis (NIH/OD) [E] < (b) (6)

Cc: Kanarek, Morgan < MKanarek@nas.edu>

Subject: For your attention

Dear Francis,

Congratulations on your launch of Public Private Partnership to speed COVID 19 vaccine and treatment options. This is very timely and much needed. Kudos to your leadership.

I am sure you are aware of a global coordinating effort to accelerate vaccines, diagnostics and therapeutics. I have been part of the conversation and planning along with Jeremy Farrar, Richard Hatchett, Seth Berkley, Chris Elias, Paul Stoffels etc. Recently WHO, Gates Foundation and European Commission have been leading the planning. This has advanced rapidly and is in the final stages in development that will be soon announced. It has involved European Commission, Germany, Japan, UK, Norway, France, Saudi as well as Gates Foundation, WHO, World Bank, Wellcome Trust, GAVI, Global Fund, CEPI, GPMB and private sector industry. The initiative will begin with a Pledge conference for \$8B as a starting point. This will be led by President von der Leyen and is co-chaired by the above country leaders. This will occur on May 4. In addition by the end of this week or early next week there will be an announcement on the global coordinating structure with will involve Gates, WHO etc.

I am writing to be sure that you and the White House are aware of these upcoming events. Can you share this information with the White House? Besides you, who else should I share this information with? I will be happy to send you background documents if you wish. Please call me anytime.

Best,

Victor

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]

 Sent:
 Tue, 21 Apr 2020 23:10:36 +0000

 To:
 Fauci, Anthony (NIH/NIAID) [E]

Subject: FW: Consideration of IM COVID Immune Globulin for Prevention of COVID-19

Infection

Attachments: Prophylactic Intramuscular COVID-IG - Oxman.pdf, FURTHER ARGUMENTS IN

FAVOR OF INTRAMUSCULAR COVID-IG Version 4 - Oxman.pdf

Email from Gary Noble, advisor to Bob Windom in the 1980s.

Robert W. Eisinger, Ph.D.

Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Gary Noble (b) (6)

Sent: Tuesday, April 21, 2020 4:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] <

Cc: McGowan, John J. (NIH/NIAID) [E] (6) (6); Conrad, Patricia (NIH/NIAID) [E]

(b) (6) >

(b) (6); Oxman, Michael (b) (6)

Subject: Consideration of IM COVID Immune Globulin for Prevention of COVID-19 Infection

Dear Tony,

I will always remember our amazing collaboration during the HIV/AIDS days in the 1980s, when I served as AIDS Advisor to Bob Windom, the DHHS Assistant Secretary for Health during President Reagan's administration. And now, I am delighted and amazed to watch you so adroitly maneuver the COVID-19 scientific policies and keep them front and center in the current White House!!

with John Zaia at City of Hope, and a Mayo/Hopkins/Michigan State consortium for a trial of IM COVID-IG as a preferred method for treatment and prevention of COVID-19.

This week, Mike expects to complete the protocol for a placebo (normal IG)-controlled trial of IM COVID-IG prophylaxis in at-risk healthcare workers

who are engaged in direct patient care at UCSD, but they need a modicum of support. Mike asked if I would reach out to see if NIAID might provide of support for this effort, using IM, as opposed to IV, COVID-IG.

I've copied Mike, who has provided the attached background information.

Tony, with all my respect and admiration for what you are doing for the U.S. and for all of us.

Gary

Gary R. Noble, MD, MPH, MA (Oxon)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 22:14:24 +0000

To: NIAID OD AM

Subject: FW: Invitation to Speak at UC Berkeley COVID-19 Hackathon

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(6) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Saahil Chadha <saahil@calhacks.io> Sent: Tuesday, April 21, 2020 11:00 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) > Subject: Invitation to Speak at UC Berkeley COVID-19 Hackathon

Dear Dr Fauci,

My name is Saahil, and I'm a director at Cal Hacks, a student organization at the University of California, Berkeley. This upcoming weekend, we will be hosting hack:now, a 36-hour global online hackathon to foster innovative and technical solutions to tackle the challenges faced around the current COVID-19 pandemic. We're projected to have 1,500 participants from around the world. I'm reaching out to invite you to be our opening ceremony speaker.

Specifically, this Friday night, April 24, from 7-8pm Pacific Daylight Time, we're going to be hosting the opening ceremony of our event. At this time, we want to inspire our hackers to help solve global challenges related to health and community. We would be absolutely honored if you would join us to speak at our opening ceremony for just a few minutes to share your experiences with and response to the COVID-19 pandemic. Your unique perspective and expanse of knowledge makes you the most qualified person, and we would be humbled to include you as our opening ceremony speaker. Please let us know if you are able to accept this invitation.

Stay safe,

Saahil Chadha

Calhacks.io

From: Fauci, Anthony (NIH/NIAID) [E] Sent: Tue, 21 Apr 2020 22:06:57 +0000

To: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]

Subject: RE: Message for Dr Anthony FAUCI

OK. Please take care of this. Thanks.

Anthony S. Fauci, MD Director National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 Phone: (b) (6) FAX: (301) 496-4409

(b) (6) E-mail:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) Sent: Tuesday, April 21, 2020 11:31 AM To: Conrad, Patricia (NIH/NIAID) [E] < (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: RE: Message for Dr Anthony FAUCI

I would be extremely grateful to you if you can provide me with the most recent and pertinent scientific and population data concerning covid-19. I know how extremely busy you are but maybe a collaborator (b) (6) of yours whether he can send me the cata via e-mail

Not exactly sure what he wants but I can send him some links that will get him the latest CoV info from pubmed, preprints, CDC etc

From: Conrad, Patricia (NIH/NIAID) [E] < (b) (6)>

Sent: Tuesday, April 21, 2020 11:16 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) > (b) (6) Cc: Folkers, Greg (NIH/NIAID) [E]

Subject: FW: Message for Dr Anthony FAUCI

Can we direct her somewhere? Gray?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jean-Louis Touraine (b) (6) >

Sent: Tuesday, April 21, 2020 11:06 AM

To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Subject: Potential SPAM: Message for Dr Anthony FAUCI

I would be very grateful to you if you can forward the following mail to Dr Anthony FAUCI.

Many thanks. Sincerely yours,

Pr Jean-Louis TOURAINE, Lyon and Paris, France.

Dear Tony,

You may remember, that we have met repeatedly and worked in parallel and in association, during the early years of the HIV epidemic.

You and I have been trained in immunoly. Both of us are much sollicitated to help facing and fighting the covid-19 epidemic.

During the past years, as well as recently, I have followed with great interest and respect your accomplishments and your advices in the fights against epidemics. I would be extremely grateful to you if you can provide me with the most recent and pertinent scientific and population data concerning covid-19. I know how extremely busy you are but maybe a collaborator of yours whether he can send me the data via e-mail (b) (6) This will allow me to give more documented informations to the French President and Government. Cooperation between countries will be crucial against covid-19 as it has been against HIV and other agents.

I look forward to seeing you again in quieter times. Many thanks and very best personal regards.

Jean-Louis TOURAINE, M.D., Ph. D., M.P.

Ce message, ainsi que les pièces jointes, sont établis, sous la seule responsabilité de l'expéditeur, à l'intention exclusive de ses destinataires ; ils peuvent contenir des informations confidentielles. Toute publication, utilisation ou diffusion doit être autorisée préalablement.

Ce message a fait l'objet d'un traitement anti-virus. Il est rappelé que tout message électronique est susceptible d'altération au cours de son acheminement sur Internet.

Vous pouvez consulter le site de l'Assemblée nationale à l'adresse suivante : http://www.assemblee-nationale.fr

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 21:39:30 +0000

To: Collins, Francis (NIH/OD) [E] ((b) (6

Cc: Myles, Renate (NIH/OD) [E]; Burklow, John (NIH/OD) [E]; Billet, Courtney

(NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]

Subject: FW: STAT: Director of U.S. agency key to helming vaccine development leaves

role suddenly amid coronavirus pandemic https://bit.ly/2XRZqKa

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >

Sent: Tuesday, April 21, 2020 3:01 PM

Subject: STAT: Director of U.S. agency key to helming vaccine development leaves role suddenly amid

coronavirus pandemic https://bit.ly/2XRZqKa

Director of U.S. agency key to helming vaccine development leaves role suddenly amid coronavirus pandemic

By Nicholas Florko @Nicholas Florko April 21, 2020



Rick Bright HHS

WASHINGTON — Rick Bright, one of the nation's leading vaccine development experts and the director of the Biomedical Advanced Research and Development Authority, is no longer leading the organization, officials told STAT.

The shakeup at the agency, known as BARDA, couldn't come at a more inopportune time for the office, which invests in drugs, devices, and other technologies that help address infectious disease outbreaks and which has been at the center of the government's coronavirus pandemic response.

Bright, whose departure was confirmed by three industry sources and two current Trump administration sources, will instead move into a narrower role at the National Institutes of Health overseeing a similar but <u>limited public-private partnership aimed at vaccine development</u>. Gary Disbrow, Bright's former deputy at BARDA, will serve as the acting director of the office, an HHS spokesperson confirmed to STAT.

BARDA was expected to play an even larger role in the coming months; Congress more than tripled BARDA's budget in the most recent coronavirus stimulus package. Already, the office has a role in some of the splashiest Covid-19 projects, including partnerships with Johnson & Johnson and Moderna Therapeutics, both of which are developing potential Covid-19 treatments.

Related:

This tiny federal agency was built to respond to a crisis like coronavirus. Now that it's here, is BARDA ready?

BARDA has been plagued with management issues virtually since its creation in 2006, with much of the criticism aimed at a contracting department that some say is unresponsive to industry partners. The office has only had two permanent directors since its creation in 2006. Bright has led the organization since 2016.

None of the sources articulated the reason for Bright's departure, though several mentioned recent chafing between Bright and Bob Kadlec, the HHS Assistant Secretary for Preparedness and Response, which has oversight over BARDA.

An HHS spokesperson confirmed that Bright will work on a recently announced NIH public-private partnership with 16 drug makers aimed at developing vaccines and treatments for Covid-19. "Dr. Rick Bright will transfer the skills he has applied as Director of the [BARDA] to the [NIH]. ... Dr. Bright brings extensive experience and expertise in facilitating powerful public-private partnerships that advance the health and well-being of the American people," the spokesperson said. Bright did not immediately respond to requests for comment.

Bright's career has largely centered around vaccine and drug development. His work at the Centers for Disease Control and Prevention focused on influenza viruses, antiviral drugs and tests. He has also worked in the biotechnology industry and served as an advisor to the World Health Organization. Before becoming BARDA director, he led the agency's Influenza and Emerging Infectious Diseases Division. Lev Facher contributed reporting.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 21:18:24 +0000

To: Crawford, Chase (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E];McGowan, John J. (NIH/NIAID) [E];Harper, Jill (NIH/NIAID) [E];Gilles, Sharon (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E];Johnson, Martin S. (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E]

Cc: Haskins, Melinda (NIH/NIAID) [E];Selgrade, Sara (NIH/NIAID) [E]

Subject: RE: Attention: COVID-19 legislative package bill text released

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409
E-mail:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b) (6)> From: Crawford, Chase (NIH/NIAID) [E] Sent: Tuesday, April 21, 2020 3:27 PM To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)'>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] (b) (6)>: Lane, Cliff (NIH/NIAID) [E] (b) (6); Johnson, Martin S. (NIH/NIAID) [E] (b) (б); Billet, (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6) Courtney (NIH/NIAID) [E] Cc: Haskins, Melinda (NIH/NIAID) [E] (b) (6); Selgrade, Sara (NIH/NIAID) [E] (b) (6) Subject: Attention: COVID-19 legislative package bill text released

Importance: High

Good Afternoon,

At 4p.m. today (4/21), the U.S. Senate is expected to hold a vote by unanimous consent on the "Paycheck Protection Program and Health Care Enhancement Act" (bill text attached). In particular please note that the legislative package includes

the following supplemental appropriations for diagnostic testing (pages 13-15 of attached):

- NIH/OD not less than \$1B to develop, validate, improve, and implement testing and associated technologies; to accelerate research, development, and implementation of point of care and other rapid testing; and for partnerships with governmental and non-governmental entities to research, develop, and implement the activities outlined in this proviso.
 - funds in the preceding proviso may be transferred to the accounts of the Institutes and Centers of the National Institutes of Health for the purposes specified in the preceding proviso
 - the transfer authority provided in the preceding proviso is in addition to all other transfer authority available to the NIH
- NCI not less than \$306M to develop, validate, improve, and implement serological testing and associated technologies for the purposes specified under this paragraph in this Act:
- NIBIB not less than \$500M to accelerate research, development, and implementation of point of care and other rapid testing related to coronavirus:
- CDC not less than \$1B for surveillance, epidemiology, laboratory capacity expansion, contact tracing, public health data surveillance and analytics infrastructure modernization, disseminating information about testing, and workforce support necessary to expand and improve COVID–19 testing
- BARDA not less than \$1B for necessary expenses of advanced research, development, manufacturing, production, and purchase of diagnostic, serologic, or other COVID–19 tests or related supplies, and other activities related to COVID–19 testing at the discretion of the Secretary
- FDA \$22M to support activities associated with diagnostic, serological, antigen, and other tests, and related administrative activities

We will keep you updated on any developments related to this legislation. Please let us know if you have any questions.

Thanks, Chase
 From:
 Fauci, Anthony (NIH/NIAID) [E]

 Sent:
 Tue, 21 Apr 2020 21:01:27 +0000

 To:
 Billet, Courtney (NIH/NIAID) [E]

Subject: RE: Ryan Zimmerman

If cleared, I would love to.

(b)(5) - PCP

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409
E-mail:
(b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)

Sent: Tuesday, April 21, 2020 4:43 PM

To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6) >

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) ; Routh, Jennifer (NIH/NIAID) [E] (b) (6) ; Stover, Kathy (NIH/NIAID) [E] (b) (6) ; Folkers, Greg

(NIH/NIAID) [E] (b) (6)

Subject: Ryan Zimmerman

Would you be interested in doing something with Ryan Zimmerman? Format TBD. We'll pursue further discussion if you give the green light.

From: Billet, Courtney (NIH/NIAID) [E] Sent: Tuesday, April 21, 2020 4:41 PM

To: Judee Ann Williams < judeeann.williams@caa.com>

Cc: Christine Lancman < christine.lancman@caa.com; Routh, Jennifer (NIH/NIAID) [E]

(b) (6)

Subject: RE: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Hi – thanks for your message – we will check and someone will get back to you in the next few days. One caveat is that as a Federal official, Dr. Fauci cannot be associated with fundraising in any way. Please confirm that is something you would be able to work around?

From: Judee Ann Williams < judeeann.williams@caa.com>

Sent: Monday, April 20, 2020 5:21 PM

To: Routh, Jennifer (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E]

(b) (6)>

Cc: Christine Lancman < christine.lancman@caa.com>

Subject: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Jennifer & Courtney-

Hello! Our friends from Steph Curry's team passed along your contact information to us and we work at CAA where we represent World Series Champion, Ryan Zimmerman.

Ryan wanted to express his gratitude first & foremost to Dr. Fauci, the entire team and all those behind the scenes working around the clock.

Ryan recently launched the Pros for Heroes Covid-19 Fund last week, with more than 30 professional athletes supporting and over \$300,000 raised across 1,400 separate donations.

(www.prosforheroes.org). Since its launch last Tuesday, contributions from the Pros For Heroes Fund have gone directly towards PPE needs throughout the Inova hospital network throughout the mid-Atlantic and have helped provide meals to those critical care front-line workers - keeping these front-line heroes covered at work and comfortable at home.

If Dr. Fauci was up to it, Ryan would love to host either a short 15 minute Q&A on his Facebook to continue raising awareness for how we need to be responding to the ongoing crisis. Or even simply thank Dr. Fauci for the tireless work he is doing and shine a light on how folks can support these critical frontline workers.

We are also open to what you think would work best! Would there any openings that would work best?

We know Dr. Fauci is big baseball fan, and of course we are all huge fans of his! If we can ever be supportive or help navigate anything in the world of pop culture, please do not hesitate to ask.

Warmest wishes,

Judee Ann

Pros For Heroes

"Teamwork is the ability to come together towards a common goal. We are looking forward to attracting as many supporters to help join this cause and give back as much as we can to those who have given us so much," said Washington National All-Star, Ryan Zimmerman, the fund's founder.

Social Links:

https://www.instagram.com/prosforheroes/ https://twitter.com/prosforheroes

Today Show:

https://www.today.com/video/ryan-zimmerman-talks-pros-for-heroes-fund-for-feeding-health-careworkers-82202693577

Washington Post Launch Article:

https://www.washingtonpost.com/sports/2020/04/14/nationals-ryan-zimmerman-starts-fund-health-care-workers-with-100k-gift/

This e-mail and any files transmitted with it are intended solely for the use of the individual or entity to whom they are addressed. If the reader of this e-mail is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any use dissemination, forwarding, printing or copying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients are free to do their best work without experiencing harassment and want to ensure they have the relevant resources they need. Clients can go to https://www.caa.com/legal/sexual-harassment-guidelines-caa-clients to learn more about their rights, and how to report violations.

 From:
 Fauci, Anthony (NIH/NIAID) [E]

 Sent:
 Tue, 21 Apr 2020 20:44:40 +0000

 To:
 Conrad, Patricia (NIH/NIAID) [E]

Cc: Billet, Courtney (NIH/NIAID) [E];clane@niaid.nih.gov

Subject: RE: urgent: CNN request

Cliff should do this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >

Sent: Tuesday, April 21, 2020 4:41 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Fwd: urgent: CNN request

Sent from my iPhone

Begin forwarded message:

From: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) >

Date: April 21, 2020 at 4:31:46 PM EDT

To: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>

Subject: Fwd: urgent: CNN request

Sent from my iPhone

Begin forwarded message:

From: "Billet, Courtney (NIH/NIAID) [E]" < (6) (6)

Date: April 21, 2020 at 2:49:39 PM EDT

To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)

Cc: "Routh, Jennifer (NIH/NIAID) [E]" (b) (6)

Subject: FW: urgent: CNN request

Patty – can you please check with Dr. Fauci if he'd like to speak to Elizabeth Cohen about the treatment guidelines.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6) >

Sent: Tuesday, April 21, 2020 2:48 PM

To: Billet, Courtney (NIH/NIAID) [E] (b) (6); Pau, Alice (NIH/NIAID) [E] (b) (6) >

Cc: Doepel, Laurie (NIH/NIAID) [E] (b) (6); Masur, Henry (NIH/CC/CCMD) [E] (b) (6); Myles, Renate (NIH/OD) [E]

(b) (6) >

Subject: Re: urgent: CNN request

I think Dr. Fauci would want the option of first refusal. He has anticipated he will be asked about these.

From: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)

Date: Tuesday, April 21, 2020 at 1:35 PM

To: "Pau, Alice (NIH/NIAID) [E]" (b) (6) >

Cc: Laurie Doepel (b) (6) , "Masur, Henry (NIH/CC/CCMD) [E]" (b) (6) , "Lane, Cliff (NIH/NIAID) (E]" (b) (6) >

Subject: RE: urgent: CNN request

HI Alice – thanks for sending this along. We will confer about how best to handle media requests about the guidelines – we're calling them NIH guidelines and the press release came from NIH, so I'd like to involve the NIH media office in this, hence I've cc'd Renate Myles. I think it's sort of an unsettled question as to who the spokespeople will be. Drs. Lane and Masur – do you have a preference?

Also, who is Claire? (The person who forwarded the CNN request to you and Dr. Masur. Would be good to have a last name so we can confer with her as needed going forward.)

From: Pau, Alice (NIH/NIAID) [E] (b) (6)>

Sent: Tuesday, April 21, 2020 1:24 PM

To: Billet, Courtney (NIH/NIAID) [E] (b) (6)

Cc: Doepel, Laurie (NIH/NIAID) [E] (b) (6) Masur, Henry (NIH/CC/CCMD) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6) >

Subject: FW: urgent: CNN request

Hi Courtney,

Please see below the request from CNN. Per Laurie, I will forward other requests to you.

Thanks, Alice

From: COVID19 Treatment Guidelines < COVID19TreatmentGuidelines@nih.gov > Date: Tuesday, April 21, 2020 at 1:06 PM

To: Henry Masur (b) (6), Alice Pau

(b) (6) >

Subject: Fw: urgent: CNN request

Hi Henry and Alice,

I am not sure how we want to handle interview requests like this. Would someone on the Panel want to/be allowed to speak to the press about the guidelines?

I am happy to politely decline if we want to handle it that way.

It is nice to see that we are being picked up by the press already though. I am glad people are already expressing interest.

Just let me know! Claire

From: Nigam, Minali < Minali. Nigam@turner.com>

Sent: Tuesday, April 21, 2020 4:03 PM

To: COVID19 Treatment Guidelines < COVID19TreatmentGuidelines@nih.gov> Cc: Cohen, Elizabeth < Elizabeth.Cohen@turner.com>; Fine, Amanda (NIH/OD)

[E] (b) (6) > Subject: urgent: CNN request

To the NIH Covid-19 Treatment Guideline Team:

My name is Minali Nigam and I work with Elizabeth Cohen at CNN Health. We wanted to reach out and request to speak with someone over the phone involved with the NIH treatment guidelines for covid-19. Please let us know as soon as possible for an available time today.

We appreciate your help, as we inform our viewers of important health information.

Best, Minali

Dr. Minali Nigam CNN Health

(b) (6)

(b))(5) - PCP

(b)(5) - PCP

(b)(5) - PCP

(b)(5) - PCP


(b)(5) - PCP


(b)(5) - PCP


		(b)(5) - PCP

(b)(5) - PCP

(b)(5)	- PCP







(b)(5) - PCP



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 19:42:03 +0000

To: Birx, Deborah L. EOP/NSC;Hahn, Stephen;Redfield, Robert R. (CDC/OD)

Subject: FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and

mutations affect deadliness of strains, Chinese study finds

See below

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263

Phone: (301) 496-226 FAX: (301) 496-4409

E-mail: afauci@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)

Sent: Monday, April 20, 2020 1:53 PM

Subject: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect

deadliness of strains, Chinese study finds

China / Science

Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

- The most aggressive strains of Sars-CoV-2 could generate 270 times as much viral load as the least potent type
- New York may have a deadlier strain imported from Europe, compared to less deadly viruses elsewhere in the United States



Stephen Chen in Beijing

Published: 10:41pm, 20 Apr, 2020 Updated: 1:33am, 21 Apr, 2020



A team led by Professor Li Lanjuan has studied how the novel coronavirus mutates and possible implications for the pandemic. Photo: EPA-EFE

A new study by one of China's top scientists has found the ability of <u>the new coronavirus</u> to mutate has been vastly underestimated and different strains may account for different impacts of the disease in various parts of the world.

Professor Li Lanjuan and her colleagues from Zhejiang University found within a small pool of patients many mutations not previously reported. These mutations included changes so rare that scientists had never considered they might occur.

They also confirmed for the first time with laboratory evidence that <u>certain mutations could create</u> strains deadlier than others.

"Sars-CoV-2 has acquired mutations capable of substantially changing its pathogenicity," Li and her collaborators wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday. Li's study provided the first hard evidence that mutation could affect how severely the virus caused disease or damage in its host.

Li took an unusual approach to investigate the virus mutation. She analysed the viral strains isolated from 11 randomly chosen Covid-19 patients from Hangzhou in the eastern province of Zhejiang, and then tested how efficiently they could infect and kill cells.

The deadliest mutations in the Zhejiang patients had also been found in most patients across Europe, while the milder strains were the predominant varieties found in parts of the United States, such as Washington state, according to their paper.

A separate study had found that New York strains had been imported from Europe. The death rate in New York was similar to that in many European countries, if not worse.

But the weaker mutation did not mean a lower risk for everybody, according to Li's study. In Zhejiang, two patients in their 30s and 50s who contracted the weaker strain became severely ill. Although both survived in the end, the elder patient needed treatment in an intensive care unit.

This finding could shed light on differences in regional mortality. The pandemic's infection and death rates vary from one country to another, and many explanations have been proposed.

Genetic scientists had noticed that the dominant strains in different geographic regions were inherently different. Some researchers suspected the varying mortality rates could, in part, be caused by mutations but they had no direct proof.

The issue was further complicated because survival rates depended on many factors, such as age, underlying health conditions or even blood type.

In hospitals, Covid-19 has been treated as one disease and patients have received the same treatment regardless of the strain they have. Li and her colleagues suggested that defining mutations in a region might determine actions to fight the virus.

"Drug and vaccine development, while urgent, need to take the impact of these accumulating mutations ... into account to avoid potential pitfalls," they said.

Li was the <u>first scientist to propose the Wuhan lockdown</u>, according to state media reports. The government followed her advice and in late January, the city of more than 11 million residents was shut down overnight.

The sample size in this most recent study was remarkably small. Other studies tracking the virus mutation usually involved hundreds, or even thousands, of strains.

Li's team detected more than 30 mutations. Among them 19 mutations – or about 60 per cent – were new.

They found some of these mutations could lead to functional changes in the virus' spike protein, a unique structure over the viral envelope enabling the coronavirus to bind with human cells. Computer simulation predicted that these mutations would increase its infectivity.

To verify the theory, Li and colleagues infected cells with strains carrying different mutations. The most aggressive strains could generate 270 times as much viral load as the weakest type. These strains also killed the cells the fastest.

It was an unexpected result from fewer than a dozen patients, "indicating that the true diversity of the viral strains is still largely underappreciated," Li wrote in the paper.



Professor Li Lanjuan is a leading Chinese epidemiologist. Photo: Xinhua

The mutations were genes different from the earliest strain isolated in Wuhan, where the virus was first detected in late December last year.

The coronavirus changes at an average speed of about one mutation per month. By Monday, more than 10,000 strains had been sequenced by scientists around the globe, containing more than 4,300 mutations, according to the China National Centre for Bioinformation.

Most of these samples, though, were sequenced by a standard approach that could generate a result quickly. The genes were read just once, for instance, and there was room for mistakes.

Li's team used a more sophisticated method known as ultra-deep sequencing. Each building block of the virus genome was read more than 100 times, allowing the researchers to see changes that could have been overlooked by the conventional approach.

The researchers also found three consecutive changes – known as tri-nucleotide mutations – in a 60-year-old patient, which was a rare event. Usually the genes mutated at one site at a time. This patient spent more than 50 days in hospital, much longer than other Covid-19 patients, and even his faeces were infectious with living viral strains.

"Investigating the functional impact of this tri-nucleotide mutation would be highly interesting," Li and colleagues said in the paper.

Professor Zhang Xuegong, head of the bioinformatics division at the National Laboratory for Information Science and Technology at Tsinghua University, said ultra-deep sequencing could be an effective strategy to track the virus' mutation.

"It can produce some useful information," he said.

But this approach could be much more time consuming and costly. It was unlikely to be applied to all samples.

"Our understanding of the virus remains quite shallow," Zhang said. Questions such as where the virus came from, why it could kill some healthy young people while generating no detectable symptoms in many others still left scientists scratching their heads.

"If there is a discovery that overturns the prevailing perception, don't be surprised."

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 18:01:06 +0000

To: Jim Yong Kim Subject: RE: My article

Jim:

Very nice paper! Thanks for sending it.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jim Yong Kim < Jim. Yong. Kim@global-infra.com>

Sent: Monday, April 20, 2020 3:00 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Subject: My article

Tony,

Hope you're well and thank you again for all that you are doing. I got this out today in the New Yorker and I'll be talking to most of the Democratic caucus today about what we're doing in Mass and the developing world.

Hang in there and let me know if there is anything more I can do. Mass is tough but we're going to have a 1000 contact tracers very soon. Every day we learn so much, which is why it's so important for everyone to get started.

Jim

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 17:43:21 +0000

To: EDWARD SCOLNICK

Cc: Mascola, John (NIH/VRC) [E]; Cassetti, Cristina (NIH/NIAID) [E]; Marston, Hilary

(NIH/NIAID) [E]

Subject: RE: for your consideration

Attachments: Scientists_to_Stop_COVID19_2020_04_15_FINAL.pdf

Ed:

Thank you for your note and for sending this. The outline that you provide is exactly in sync with what we are already doing and have definitive plans to do with regard to classic antivirals, monoclonal antibodies, and a variety of vaccine candidates. As you know, the candidate developed here at NIH in collaboration with Moderna is well into phase 1 trials and at least 2 others are entering into phase 1 trials.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

```
From: EDWARD SCOLNICK
Sent: Sunday, April 19, 2020 5:18 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: David R. Liu
(b) (6) Schreiber, Stuart
(b) (6) Ramnik Xavier
(b) (6) Subject: for your consideration

(b) (6) Start (b) (6) Subject: for your consideration
```

Tony . I hope your mail box is not so full that there is room for this. A group of concerned scientists from different parts of the country was organized to try to encapsulate and focus the national effort against Covid. This document has been shared with the White House although we are not sure if it has had any effect on their plans. It has also been shared with The Gates Foundation and a few other business and academic leaders. We think we have been fairly comprehensive in our considerations and recommendations. I hope you will find this helpful. We would greatly appreciate a conversation with you after you have had an opportunity to digest the content of the proposal. If there is anything else we can do to help you in this National emergency, we stand ready to help. When I was at Merck, we led the successful

effort to make HIV a manageable disease and we dramatically lowered the death rate as a result of the drugs we made and the first triple therapy trial during the HIV pandemic. We hope we can help do the same for The Covid Pandemic Best wishes Ed scolnick

 From:
 Fauci, Anthony (NIH/NIAID) [E]

 Sent:
 Tue, 21 Apr 2020 15:12:29 +0000

 To:
 Grady, Christine (NIH/CC/BEP) [E]

Subject: FW: Thank you

See part about you. ©

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >

Sent: Tuesday, April 21, 2020 11:07 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: FW: Thank you

This is a cute note...you can skip most of it and see highlight - that is the cute part

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

----Original Message---From: JOAN HUSSEY
Sent: Tuesday, April 21, 2020 9:34 AM
To: Fauci, Anthony (NIH/NIAID) [E]

(b)(6)

Subject: Thank you

Dear Dr. Fauci,

I just wanted to say thank you for everything you are doing to educate us in this country, and keep us safe during this horrendous coronavirus pandemic. I can't even begin to imagine how difficult it is to maintain your composure and persevere with your focus, being constantly in the public eye and also trying to expertly guide a president who seems more preoccupied with his own image (and sound of his own voice), and political aspirations than with the actual well being of his country's citizens.

By now, it should be perfectly clear to us that we can't have a healthy economy without a healthy population.

(b) (6
^{(6) (6)} We all have been
(b) (6)
ings to be delivered to our
^{®®} is the only one of us
store if necessary and then, he ix feet between himself and sible. In addition, (b) (6) (ve, we haven't even, any of us, le our house for months.
i

In the past two months, I've been outside only four times - twice on our deck and twice in my car, dropping off a couple of shopping bags at a friend's house and at group home - both times leaving the bags in the driveway, and then driving right back home.

I'm so thankful for FaceTime, but we miss hugs and kisses. I know all this must sound extreme, and it is, but I'm terrified of becoming a statistic so we're doing whatever we can to stay healthy for ourselves and one another.

(b) (6) My family is hearing what you're saying and taking your advice. I'm sorry this email is so long but my intention, more than anything, is to thank you for your wisdom and advice, both grounded in years of experience. I worked at NIH for about 25 years - in the CC, in NCI, and in Human Genome. I met you once, briefly, about 40 years ago (+/-) in Bldg. 31's fitness room. I had been working in the CC, in the Patient Activities Dep't. (on the POB out- and inpatient units)at the time. I was incorrectly using a piece of equipment and you were kind enough to come over and show me the correct way to use it. I recognized you immediately, and have never forgotten that experience and how gracious you were.

I'm well aware from the news that you are up against some very tough people and some very tough times but please know you also have an army of grateful followers in this country who are completely convinced that what you are advising is in their very best interest.

Thank you again for all you've done for all of us over the years. My family and I are more grateful than I can express.

PS I read all about your wife who sounds amazing also. You two make an "All-Star" team.

Be well.

Gratefully, Joan ("Joanie") Hussey

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 15:11:29 +0000

To: (b)
Subject: FW: Thank you

Joanie:

Many thanks for your kind note. It is much appreciated. Stay safe!

Best, Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

----Original Message-----

From: JOAN HUSSEY (b) (6) (c) Sent: Tuesday, April 21, 2020 9:34 AM


To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Thank you

Dear Dr. Fauci,

I just wanted to say thank you for everything you are doing to educate us in this country, and keep us safe during this horrendous coronavirus pandemic. I can't even begin to imagine how difficult it is to maintain your composure and persevere with your focus, being constantly in the public eye and also trying to expertly guide a president who seems more preoccupied with his own image (and sound of his own voice), and political aspirations than with the actual well being of his country's citizens.

By now, it should be perfectly clear to us that we can't have a healthy economy without a healthy population.



(b) (6) My family is hearing what you're saying and taking your advice. I'm sorry this email is so long but my intention, more than anything, is to thank you for your wisdom and advice, both grounded in years of experience. I worked at NIH for about 25 years - in the CC, in NCI, and in Human Genome. I met you once, briefly, about 40 years ago (+/-) in Bldg. 31's fitness room. I had been working in the CC, in the Patient Activities Dep't. (on the POB out- and inpatient units)at the time. I was incorrectly using a piece of equipment and you were kind enough to come over and show me the correct way to use it. I recognized you immediately, and have never forgotten that experience and how gracious you were.

I'm well aware from the news that you are up against some very tough people and some very tough times but please know you also have an army of grateful followers in this country who are completely convinced that what you are advising is in their very best interest.

Thank you again for all you've done for all of us over the years. My family and I are more grateful than I can express.

PS I read all about your wife who sounds amazing also. You two make an "All-Star" team.

Be well.

Gratefully, Joan ("Joanie") Hussey

Sent from my iPhone

Fauci, Anthony (NIH/NIAID) [E] From: Sent: Tue, 21 Apr 2020 14:52:49 +0000 Barasch, Kimberly (NIH/NIAID) [C] To:

Subject: FW: White House Coronavirus Task Force PowerPoint - 4.21.20

Attachments: PowerPoint April 21.pptx

Anthony S. Fauci, MD Director National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 Phone: (b) (6) FAX: (301) 496-4409

(b) (6) E-mail:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 02:52:55 +0000

To: Corey, Larry
Subject: manuscript

Attachments: COVID vaccine editorial_prefinal April20 wfigure -with Fauci tracked edits.docx

Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (6) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)

 Sent:
 Mon, 20 Apr 2020 19:24:58 -0400

 To:
 Mascola, John (NIH/VRC) [E]

 Subject:
 Fwd: COVID-19 vaccine

Let us discuss. I am not sure how to answer Adrian,

Begin forwarded message:

From: Adrian Hill (b) (6).

Date: April 20, 2020 at 6:16:30 PM EDT

To: "Fauci, Anthony (NIH/NIAID) [E]" (6) (6)>

Cc: Hildegund Ertl (b) (6) >, Sarah Gilbert (b) (6)

Subject: FW: COVID-19 vaccine

Dear Dr Fauci




Thank you for your consideration of this at an exceptionally busy time.

Yours sincerely

Adrian Hill

Professor Adrian V. S. Hill

Director, The Jenner Institute Nuffield Department of Medicine University of Oxford Old Road Campus Research Building Oxford OX3 7DQ



 From:
 Fauci, Anthony (NIH/NIAID) [E]

 Sent:
 Mon, 20 Apr 2020 20:43:18 +0000

 To:
 Conrad, Patricia (NIH/NIAID) [E]

Subject: FW: Update: White House Coronavirus Meeting - 4.21.20

Yikes...... That would make 4 days in a row without a Press Conference for me − Saturday, Sunday, Monday and tomorrow ☺ ☺

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hurst, Natalie R. EOP/OVP (b) (6)

Sent: Monday, April 20, 2020 4:38 PM

Subject: Update: White House Coronavirus Meeting - 4.21.20

Importance: High

All -

There will be no White House Coronavirus Task Force Meeting on Tuesday, April 21st.

Enjoy your evening,

Natalie Hurst

Operations Coordinator, White House Coronavirus Task Force Executive Assistant to the Chief of Staff The Office of the Vice President

(b) (6)